Clinical trial • Phase I • Neurology
Autologous EBV-specific cytotoxic T lymphocytes for Multiple sclerosis
Phase I trial of Autologous EBV-specific cytotoxic T lymphocytes for Multiple sclerosis. open-label, none/not specified-controlled. 7 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Multiple sclerosis
- Trial Stage
- Phase I
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 06-09-2024
- First CTIS Authorization Date
- 03-10-2024
Trial design
open-label, none/not specified-controlled Phase I trial across 1 site in France.
- Open Label
- Yes
- Comparator
- None/Not specified
Recruitment
- Recruitment Window Months
- 94
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 7
France
- Earliest CTIS Part Ii Submission Date
- 16-09-2024
- Latest Decision Or Authorization Date
- 12-02-2025
- Processing Time Days
- 149
- Number Of Sites
- 1
- Number Of Participants
- 7
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Neurology
- Principal Investigator Name
- David LAPLAUD
- Principal Investigator Email
- david.laplaud@chu-nantes.fr
- Contact Person Name
- David LAPLAUD
- Contact Person Email
- david.laplaud@chu-nantes.fr
- Number Of Participants
- 7
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Nantes
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Autologous EBV-specific cytotoxic T lymphocytes (CTL)
- Active Substance
- Autologous EBV-specific cytotoxic T lymphocytes
- Modality
- Cell therapy
Related trials
Other published trials that may interest you.